Contractile and relaxant responses of the canine isolated spinal artery to vasoactive substances.
1. Effects of vasoactive substances were investigated in the canine isolated spinal branch of the intercostal artery (SBICA). 2. Addition of angiotensin II (AII), vasopressin, noradrenaline (NA), adrenaline, 5-hydroxytryptamine (5-HT), and dopamine each produced concentration-dependent contraction in the SBICA, whereas prostaglandin F2 alpha, histamine, and tyramine caused only slight contraction. The decreasing order of the potency of contractile agents was AII much greater than vasopressin = NA greater than 5-HT greater than adrenaline much greater than dopamine. 3. Although the pD2 value for phenylephrine (5.31 +/- 0.36) was smaller than that for NA (6.48 +/- 0.13), there was no significant difference in Emax value between these two agonists in the SBICA. On the other hand, xylazine produced only a slight contraction, the pD2 value being 3.59 +/- 0.08. Phentolamine (10(-8)-10(-6) M) and prazosin (10(-8)-10(-6) M) competitively inhibited the NA-induced contraction, while yohimbine (10(-8)-10(-6) M) did not. 4. Acetylcholine (ACh), sodium nitroprusside (SNP), ATP, ADP, and adenosine caused concentration-dependent relaxations in SBICA following contraction with NA. On the other hand, isoprenaline up to 10(-4) M did not produce any relaxation. The decreasing order of potency of the relaxant agents was ACh greater than SNP much greater than ATP = ADP = adenosine. 5. The ACh-induced relaxation was competitively inhibited by atropine and was abolished by mechanical removal of the endothelium. Aspirin (5 x 10(-5) M) did not affect the relaxant response to ACh, while oxyhaemoglobin (10(-5) M) and methylene blue (10(-5) M) produced significant attenuation. 6. These results suggest that NA produces contraction of the isolated canine SBICA which is mainly mediated via alpha 1-adrenoceptors and that ACh causes a relaxation of the SBICA due to release of endothelium-derived relaxing factor (EDRF) from the endothelial cells.
Shirai
K
K
1st Department of Physiology, Shinshu University School of Medicine, Matsumoto, Japan.
Kawai
Y
Y
Ohhashi
T
T
D000109:Acetylcholine / Q000494:pharmacology; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D004285:Dogs; D004298:Dopamine / Q000494:pharmacology; D004347:Drug Interactions; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009126:Muscle Relaxation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D009638:Norepinephrine / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D012701:Serotonin / Q000494:pharmacology; D013116:Spinal Cord / Q000098:blood supply; D014667:Vasopressins / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D014667:Vasopressins; D000804:Angiotensin II; D012701:Serotonin; D000109:Acetylcholine; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine